我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

浅谈降压药——血管紧张素Ⅱ受体拮抗剂ARB

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第1期
页码:
120-122,126
栏目:
综述
出版日期:
2016-10-05

文章信息/Info

Title:
Antihypertensive drugs--Angiotensin II receptor blockers
作者:
田海军1; 刘海婷2; 王晓明2; 张 华2
(1.解放军第161医院干部病房，湖北 武汉 430010；
2.第四军医大学西京医院老年病科，陕西 西安 710032)
Author(s):
TIAN Hai-jun1;  LIU Hai-ting2;  WANG Xiao-ming2;  ZHANG Hua2
(1.Department of Veteran Cadres, PLA 161 Hospital, Wuhan 430010, Hubei, China；
2.Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
血管紧张素Ⅱ受体拮抗剂; 高血压; 血管紧张素受体
Keywords:
angiotensin II receptor blockers;  hypertension;  angiotensin receptor
分类号:
R541.3
DOI:
-
文献标识码:
A
摘要:
高血压是心脑血管疾病最常见的危险因素之一，而血管紧张素Ⅱ受体拮抗剂（angiotensin II receptor blockers，ARB)是作用于肾素-血管紧张素-醛固酮系统的常用抗高血压药。近年来，ARB广泛应用于临床，本文从ARB对心、脑、肾等靶器官的保护作用浅谈分析该类药物作为临床一线降压药物的原因。
Abstract:
Hypertension is one of the most common cardiovascular disease risk factors and angiotensin II receptor blockers (ARB) are antihypertensive drugs acting on the renin-angiotensin-aldosterone system. In recent years, ARB drugs have been widely used in the clinical setting. This article analyzes the reasons why ARB drugs are clinically used as the first-line antihypertensive drugs by discussing the protective role of ARB for target organs such as in cardiovascular, cerebrovascular, and kidney diseases as well as diabetes.

参考文献/References

[1]Mills KT,Bundy JD,Kelly TN,et al.Global Burden of Hypertension: Analysis of Population-based Studies from 89 Countries[J].J Hypertens,2015,33(E Suppl 2):e2.
[2]中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中国医学前沿杂志(电子版), 2011,3(5):42-93.
[3]胡大一,刘梅林,郭艺芳,等.老年高血压的诊断与治疗中国专家共识(2011版)[J].中国医学前沿杂志(电子版),2012,4(2):31-39.
[4]Daskalopoulou SS,Rabi DM,Zarnke KB,et al.The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement,Diagnosis,Assessment of Risk,Prevention,and Treatment of Hypertension[J].Can J Cardiol,2015,31(5):549-568.
[5]Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].European Heart Journal,2013,34(28):2159-2219.
[6]Armario P,de la Sierra A.Antihypertensive treatment and stroke prevention:are angiotensin receptor blockers superior to other antihypertensive agents?[J].Ther Adv Cardiovasc Dis,2009,3(3):197-204.
[7]Gerdts E,Oikarinen L,Palmieri V,et al.Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy:the Losartan Intervention for Endpoint Reduction in Hypertension(LIFE)Study[J].Hypertension,2002,39(3):739-743.
[8]Akazawa H,Yabumoto C,Yano M,et al.ARB and cardioprotection[J].Cardiovasc Drugs Ther,2013,27(2):155-160.
[9]Kyvelou SM,Vyssoulis GP,Karpanou EA,et al.Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile:an open multi-drug comparison trial[J].Hellenic J Cardiol,2006,47(1):21-28.
[10]Fagard RH,Celis H,Thijs L,et al.Regression of left ventricular mass by antihypertensive treatment:a meta-analysis of randomized comparative studies[J].Hypertension,2009,54(5):1084-1091.
[11]Han M,Zhang Y,Sun S,et al.Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation:a meta-analysis of randomized controlled trials[J].J Cardiovasc Pharmacol,2013,62(4):405-415.
[12]周 力,王翠英.血管紧张素受体阻滞剂与高血压患者房颤的一级预防[J].心脏杂志,2011,23(4):552-554.
[13]Dai X,Hummel SL,Salazar JB,et al.Cardiovascular physiology in the older adults[J].J Geriatr Cardiol,2015,12(3):196-201.
[14]Yu Y,Fukuda N,Yao EH,et al.Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension[J].Am J Hypertens,2008,21(1):72-77.
[15]Lv J,Perkovic V,Foote CV,et al.Antihypertensive agents for preventing diabetic kidney disease[J].Cochrane Database Syst Rev,2012,12:CD004136.
[16]Ferrari R,Rosano GM.Not just numbers,but years of science:Putting the ACE inhibitor-ARB meta-analyses into context[J].Int J Cardiol,2013,166(2):286-288.
[17]Mauer M,Zinman B,Gardiner R,et al.Renal and retinal effects of enalapril and losartan in type 1 diabetes[J].N Engl J Med,2009,361(1):40-51.
[18]Sj?lie AK,Klein R,Porta M,et al.Effect of candesartan on pro-gression and regression of retinopathy in type 2 diabetes(DIRECT-Protect 2):a randomised placebo-controlled trial[J].Lancet,2008,372(9647):1385-1393.
[19]Kjeldsen SE,Aksnes TA,Sierra ADL,et al.Amlodipine and valsartan:calcium channel blockers/angiotensin II receptor blockers combination for hypertension[J].Therapy,2007,4(1):31-40.
[20]Geng DF,Jin DM,Wu W,et al.Angiotensin receptor blockers for prevention of new-onset type 2 diabetes:A meta-analysis of 59,862 patients[J].Int J Cardiol,2015,155(2):236 -242.
[21]James PA,Oparil S,Carter BL,et al.2014 evidence-based guideline for the management of high blood pressure in adults:Report from the panel members appointed to the eighth joint national committee(JNC 8)[J].2014,311(5):507-520.
[22]Robles NR,Cerezo I,Hernandez-Gallego R.Renin-angiotensin system blocking drugs[J].J Cardiovasc Pharmacol Ther,2014,19(1):14-33.

备注/Memo

备注/Memo:
收稿日期：2015-11-04.基金项目：国家自然科学基金项目资助（81370928）；陕西省社会发展科技攻关项目资助（2015SF095）
通讯作者：张华，副教授，主要从事老年医学疾病研究 Email:zhanghua77@fmmu.edu.cn
作者简介：田海军，副主任医师，硕士 Email：haijunt161@163.com 共同第一作者：刘海婷，住院医师，硕士生Email：liuhaiting0918@163.com
更新日期/Last Update: 2016-10-09